Volume Active Stocks In Review: TiVo (NASDAQ:TIVO), Two Harbors Investment (NYSE:TWO), Juno Therapeutics (NASDAQ:JUNO), Chimera Investment (NYSE:CIM)

On Monday, TiVo Inc. (NASDAQ:TIVO)’s shares declined -0.28% to $10.50.

TiVo Inc. (TIVO) Reports 17% EPS Growth on Record Service and Technology Revenue and Continued Subscription Growth for the First Quarter Ended April 30, 2015.

• Diluted EPS of $0.08, up 17% relative to the year-ago quarter.
• Total TiVo subscriptions now about 5.8 million, up 27% year-over-year.
• Record Service and technology revenues of $92.4 million in the first quarter, an enhance of 7% year-over-year, surpassing guidance; driven by strong year-over-year growth in MSO and Digitalsmiths’ service revenue.
• MSO service revenue grew 41% year-over-year; Noteworthyprogress with existing distribution relationships; extended partnership with Virgin Media; Vodafone Spain bundling ONO television service powered by the cloud-based TiVo platform to its mobile customers.
• Adjusted EBITDA of $29.0 million, in line with the high-end of guidance.
• Net Income of $7.9 million, in line with the high-end of guidance; comprised of $1.8 million of interest expense, net of tax, that related to the convertible notes issued in September 2014, without which, current quarter net income would have raised by $1.6 million relative to year-ago quarter.
• Positive TiVo-Owned net additions resulted in the best first quarter net addition performance in eight years; while gross additions of 39,000 were up 22% year-over-year.
• Declared the acquisition of Cubiware, to expand to emerging Pay TV markets in addition to expanding services for international operators in other markets.
• TiVo software to be integrated into ARRIS set-top boxes; TiVo now working with all major global set-top box providers.

TiVo Inc. provides television software services and cloud-based software-as-a-service solutions that enable to view video content through various screens. It offers whole-home solutions that comprise 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, non-DVR IP set-top boxes (STBs), and software to enable streaming to application on third-party devices, such as iOS and Android mobile phones and tablets through features, such as What to Watch Now, OnePass, integrated search, access to broadband video content, and TiVo online/mobile scheduling.

Two Harbors Investment Corp (NYSE:TWO)’s shares gained 0.19% to $10.71.

Two Harbors Investment Corp (TWO) stated Lindblad’s financial results for the quarter ended March 31, 2015.

As declared formerly, Lindblad and Capitol intend to merge in a projected business combination which is anticipated to close by June 30, 2015.

First Quarter 2015 Financial Highlights

• Lindblad generated revenue of $55.4 million in the first quarter of 2015, a $4.0 million enhance over the prior year quarter, representing a 7.9% annual growth rate.
• Net Yield for the first quarter was $1,003.92, which was $56.58 higher than in the prior year quarter, representing a 6.0% annual growth rate.
• Adjusted EBITDA for the first quarter was $14.2 million, a 1.0% enhance over the prior year quarter.

Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), residential mortgage loans, mortgage servicing rights, commercial real estate debt and related assets, and other financial assets.

At the end of Monday’s trade, Juno Therapeutics Inc (NASDAQ:JUNO)‘s shares surged 0.82% to $53.07.

Juno Therapeutics Inc (JUNO) declared that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging clinical responses in patients with B-cell cancers. Clinical results will be presented in an oral presentation recently at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

In an oral presentation on Monday, June 1, 2015 by Cameron J. Turtle, MBBS, Ph.D. of the Fred Hutchinson Cancer Research Center entitled, “Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition” updated Phase I results in a total of 52 patients treated with JCAR014 against B-cell malignancies will be stated from this ongoing trial:

• Twenty-four patients with acute lymphoblastic leukemia (ALL), 23 patients with non-Hodgkin lymphoma (NHL), and 5 patients with chronic lymphocytic leukemia (CLL) were treated with JCAR014.
• CD19 CAR T cells of defined subset composition demonstrated potent anti-tumor activity: CR as documented by flow cytometry was observed in 21/23 (91%) of evaluable patients with relapsed or refractory (r/r) B-cell ALL; complete or partial responses were observed in 12/19 (63%) of patients with r/r NHL; and complete responses were obtained in 2/5 patients with r/r chronic lymphocytic leukemia.
• Translational insights comprised of:
  • Dramatically improved CAR T cell peak and persistence following optimization of the lymphodepletion conditioning regimen.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates comprise JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies.

Chimera Investment Corporation (NYSE:CIM), ended its Monday’s trading session with 0.55% gain, and closed at $14.51.

Chimera Investment Corporation (CIM) declared its financial results for the first quarter of 2015 as follows:

1^st Quarter 2015 Financial Highlights

• Average earning assets grew to $15.2 billion for the quarter ended March 31, 2015 from $10.0 billion in average assets for the year ended December 31, 2014 based on amortized cost
• Net income of $67 million, up from $6 million earned in the 4^thquarter of 2014
• Core earnings of $0.59 per share compriseent with the 4^thquarter of 2014⁽¹⁾
• Net interest income of $183 million, up from $177 million in the 4^thquarter of 2014
• GAAP book value of $17.14 per share, down from $17.55 per share for the 4^thquarter of 2014
• Economic book value of $15.70 per share, down from $15.90 per share for the 4^thquarter of 2014

The Company declared a common stock dividend of $0.48 per share for the quarter ended March 31, 2015. The annualized dividend yield on the Company’s common stock for the quarter ended March 31, 2015 was 12%.

Leverage was 3.7:1 and recourse leverage was 2.6:1 at March 31, 2015.

Chimera Investment Corporation operates as a real estate investment trust in the United States. The company, through its auxiliaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes. Its targeted asset classes comprise non-agency RMBS, such as investment-grade and non-investment grade classes; agency RMBS; interest-only RMBS; and first or second lien loans secured by multifamily properties, mixed residential or other commercial properties, retail properties, office properties, and industrial properties.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.